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Background: Oral etoposide is commonly used in palliative treatment of childhood
and young adult cancer without robust evidence. We describe a national, unselected
cohort of young people in England treated with oral etoposide using routinely col-
lected, population-level data.
Methods: Patients aged under 25 years at cancer diagnosis (1995–2017) with a treat-
ment record of single-agent oral etoposide in the Systemic AntiCancer Dataset (SACT,
2012–2018)were identified, linked to national cancer registry data usingNHSnumber
and followed to 5 January 2019. Overall survival (OS) was estimated for all tumours
combined and by tumour group. A Cox model was applied accounting for age, sex,
tumour type, prior and subsequent chemotherapy.
Results: Total 115 patients were identified during the study period. Mean age was
11.8 years at cancer diagnosis and 15.5 years at treatmentwith oral etoposide.Median
OS was 5.5 months from the start of etoposide; 13 patients survived beyond 2 years.
Survival was shortest in patients with osteosarcoma (median survival 3.6 months) and
longest in CNS embryonal tumours (15.5 months). Across the cohort, a median of one
cycle (range one to nine) of etoposide was delivered. OS correlated significantly with
tumour type and prior chemotherapy, but not with other variables.
Conclusions: This report is the largest series to date of oral etoposide use in childhood
and young adult cancer. Most patients treated in this real world setting died quickly.
Despite decades of use, there are still no robust data demonstrating a clear benefit of
oral etoposide for survival.
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1 INTRODUCTION
Most children with cancer in England are either recruited to clinical
trials at diagnosis1 or treated according to clinical guidelines based
on phase III clinical trial evidence.2 Five-year survival has successively
increased for decades and in England is now 84% for all childhood can-
cers combined.3 However, at recurrence phase III trial data are scarce
and treatment relies on less robust evidence.
Oral etoposide is widely used both as a single agent and as a com-
ponent of multiagent therapy for childhood and young adult cancers.
Given orally as a single agent in the relapse setting, it is most com-
monly used as a palliative treatment, usually towards the end of life
on completion of more intensive, hospital-based regimens. The out-
comes of little more than 400 children and young adults treated with
this regimen have been reported in the literature, comprised entirely
of retrospective series, phase I and phase II studies (Table 1).4–24
Additional reports have detailed pharmacokinetic data but not patient
outcomes.25–27 There have been no phase III randomised studies
demonstrating its superiority over no treatment. The series that have
specifically reported imaging or survival outcomes after oral etoposide
are small (median n = 14, range 1–83). The most common tumours
reported are Ewing sarcoma (n = 81 from seven reports), ependy-
moma (n= 69 from seven reports), low- and high-grade gliomas (n= 67
from six reports) and neuroblastoma (n = 63 from five reports). Most
reports have documented imaging response rates, but with variation
in the time points and assessment criteria used, and etoposide doses
and schedules have varied.No large series has reportedoverall survival
(OS). Thus, although oral etoposide is a long-established and widely
used treatment for childhood cancer, evidence to support its use is
weak.
Since April 2012, information on all systemic anticancer treatments
given to individualswith a diagnosis of cancer or registrable benign and
borderline intracranial and intraspinal tumours diagnosed and treated
in England has been collected by Pubic Health England under legal
permissions granted by Section 251 of the National Health Service
Act 2006.28 The dataset has been reported previously29 and currently
includes data from April 2012 toMarch 2018 inlusive. We report here
the outcomes of a national cohort of children and young people aged
under 25 years at the date of initial cancer diagnosis who had a record




All children, teenagers and young adults (CTYA) aged under 25 years
at diagnosis with a primary malignant cancer or any registrable non-
malignant intracranial/intraspinal tumour diagnosed and resident in
England in the calendar years 1995–2017 inclusive were identified
using the national cancer registration dataset of the National Can-
cer Registration and Analysis Service (NCRAS). Patients were included
if they had at least one record of etoposide administered via the
oral route and as a single agent recorded in the systemic anti-cancer
therapy (SACT) dataset, regardless of their age at etoposide pre-
scription or the timing of oral etoposide relative to other SACT
regimens.
Data collectionwithin theSACTdatasetwaspiloted fromApril 2012
and was mandatory from April 2014. Patients who were only pre-
scribed oral etoposide before April 2012 or after March 2018 were
not captured in the cohort. Two patients had more than one tumour
recorded; for this study only the first tumour diagnosis was included
in the analysis.
2.2 Data sources and specification
Patient and tumour characteristics were obtained from the national
cancer registration dataset30: diagnosis date, age at diagnosis, sex, vital
status, date of death and cancer type. Variables relating to etoposide
treatment were obtained from the SACT dataset. The SACT dataset
is described in reference.31 In summary, a defined dataset of patient
details and prescribed treatments obtained from all electronic and
paper records are uploadedmonthly by one ormore registered upload-
ers at all NationalHealth Service (NHS) hospitals in England to a secure
portal maintained by Public Health England. The inclusion of all pub-
lic hospitals ensures that data are collected from both childhood and
TYA ‘principal treatment centres’ and from other hospitals responsible
for delivering oncology care. The following data were extracted from
thedataset for this analysis: first prescriptiondate (regimen start date),
cycle number, cycle ID, cycle date, route of administration and number
of prior lines of chemotherapy. Treatment intent is collectedwithin the
dataset, but there are known quality issueswith the data and it was not
included in the analysis. The percentage completeness for the major
data fields forCTYApatients are reported byBright et al. for the period
April 2017 to March 2018. SACT data were linked to national cancer
registry data using NHS number, a centrally allocated number unique
to each individual. Caseswithout anNHSnumber (0.75%of all registra-
tions during the period) were excluded. Dates of death were obtained
from NHS Digital. Cases were followed up until 5 January 2019, at
which point the few cases still alive were censored. The date used to
determine OS was either date of death or, for patients still alive, the
date of censoring. There was no evidence that any patients emigrated
or were otherwise lost fo follow-up. First prescription date and drug
names were also obtained for SACT regimens prescribed subsequent
to oral etoposide.
Cancer type was defined according to the International Classifica-
tion of ChildhoodCancer, 3rd edition (ICCC3).2 Only two patientswith
carcinomas were recorded to have had oral etoposide, thus it was not
felt necessary to follow the expanded classification of carcinomas in
the standard grouping of TYA cancers. Cancer subtypes IXd.1 ‘Ewing
tumour and Askin tumour of soft tissue’ and IXd.2 ‘primitive neuroec-
todermal tumours of soft tissue’ from the ICCC3 classification were
grouped with VIIIc ‘Ewing tumour and related sarcomas of bone’ and
combined into a single category, ‘Ewing sarcoma family of tumours’.
Cancer types with a count ≥10 were analysed as distinct categories;
the remaining caseswere aggregated into a categoryof ‘other tumours’.
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TABLE 2 Baseline characteristics and cycles of etoposide prescribed
N
Median age in years (IQR):
initial cancer diagnosis




Ewing sarcoma 21 14.0 (11.0–20.0) 16.7 (13.1–20.9) 3 (1–9)/19%
Osteosarcoma 18 14.5 (12.2–16.8) 18.2 (15.0–20.3) 1 (1–4)/22%
Embryonal CNS tumour 16 8.0 (2.5–12.2) 12.5 (3.8–19.5) 1 (1–5)/38%
Neuroblastoma 13 3.0 (1.0–5.0) 5.7 (1.9–7.8) 2 (1–6)/31%
Ependymoma 10 7.0 (1.8–8.8) 13.8 (8.1–18.8) 2 (1–2)/40%
Othera 37 16.0 (8.0–20.0) 18.5 (11.3–23.9) 1 (1–9)/32%
Total 115 12.0 (5.0–18.0) 16.4 (10.1–20.9) 1 (1–9)/30%
aAcute lymphoid leukaemia, acute myeloid leukaemia, unspecified and other leukaemia, Hodgkin lymphoma, astrocytoma, oligodendroglioma, pineal
parenchymal tumours and unspecified CNS neoplasms, Wilms tumour, hepatoblastoma, chondrosarcoma, rhabdomyosarcoma, fibroblastic and myofibrob-
lastic tumours, liposarcoma, CNS germ cell tumour, extracranial germ cell tumour, thyroid carcinoma, other carcinoma, unclassified.
Treatment start dates and cycle start dates were available for all
patients. However, the number of chemotherapy cycles prescribed is
known to have low data quality, particularly for orally administered
SACT as multiple cycles can be prescribed at one time to be taken by
a patient at home.32 Therefore, the number of oral etoposide cycles
prescribed per patient was derived by comparing three independent
data items: the number of distinct cycles recorded, the number of dis-
tinct cycle start dates recorded and the highest recorded cycle num-
ber. Where there was agreement between all three data items, the
number of cycles was retained, in all other cases it was recorded as
missing.
2.3 Statistical analysis
Descriptive statistics were calculated for the cohort as a whole (all
tumour types) andby tumour type. Survival in dayswas calculated from
the date of first prescription of oral etoposide, recorded in the SACT
dataset as ‘regimen start date’.
OS analysis was performed using Kaplan–Meier plots and Cox pro-
portional hazards regression. Kaplan–Meier plots were computed for
all tumour types combined and by tumour type. Log rank tests were
used to establish whether there was heterogeneity in observed differ-
ences between tumour types.
Univariable Cox regression models were used to calculate hazard
ratios (HRs) and 95% confidence intervals for death for the variables
age (as a continuous variable), tumour type and sex, and a multivari-
able model adjusting for all variables included in the model. Wald tests
were carried out to determine which associations were statistically
significant.
All analyses were performed in R v.3.5.3.33
3 RESULTS
In total, there were 145,657 tumours diagnosed in children and young
people during the study period, of which 133,385 were not associated
with a record in the SACT database, and 12,155 had SACT records
that did not include etoposide given as a single agent and adminis-
tered orally. Two second primary tumours were excluded. Therefore,
115 children and young people received orally administered etoposide
as a single agent during the study period for a first primary tumour
and were included in the study population. Ten patients were still
alive at the date of censoring. Cancer diagnoses included Ewing sar-
coma (n = 21), osteosarcoma (n = 18), embryonal central nervous sys-
tem (CNS) tumours (n = 16), neuroblastoma (n = 13), ependymoma
(n= 10) and other tumours (n= 37). Baseline characteristics are shown
in Table 2. The ‘other’ tumour group included cases from every main
group in the ICCC3 except retinoblastoma (Table 2). Mean patient age
at initial cancer diagnosis was 11.8 years (±SD 7.2 years) and mean
age at first cycle of oral etoposide was 15.5 years (±8.4 years). Year of
initial cancer diagnosis was as follows: 1995–2004 (10 cases); 2005–
2009 (16 cases), 2010–2014 (62 cases), 2015–2017 (27 cases).Median
time between initial cancer diagnosis and treatment with oral etopo-
side was 2.3 years (IQR 1.4–4.2 years) (Figure 1). A total of 93 cases
(80%) had received one or more lines of chemotherapy prior to oral
etoposide.
MedianOS fromdate of first prescription of etoposide for thewhole
cohort was 5.5 months (Figure 2A). One- and 2-year survivals were
26.4% (95% CI 19.4–36.0%) and 13.7% (8.5–22.1%), respectively. In
total, 13 patients (11%) survived beyond 2 years from the date of the
first etoposide prescription, of whom five were still alive at the censor
date. No secondmalignancies were observed after treatment with oral
etoposide. Differences in OS were apparent between tumour types
(Figure 2B). Patients with osteosarcoma and Ewing sarcoma had the
worst survival (median 3.6 and 4.0 months, respectively, Table 3). No
patient with Ewing sarcoma was observed to survive beyond 1 year
from the start of treatment. A single patient with osteosarcoma sur-
vived beyond 1 year. In contrast, individuals with ependymomas and
CNS embryonal tumours had the longest median survival (9.2 and
15.5 months, respectively) and included a single 5-year survivor with
ependymoma.
The number of prescribed cycles could be confidently derived in
81/115cases (70%) (Table2). For these cases, thenumberof prescribed
cycles was small: a median of one cycle of etoposide was prescribed
to patients with osteosarcoma, embryonal CNS tumours and ‘other
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F IGURE 1 Time interval between initial cancer diagnosis and first recorded prescription of oral etoposide
TABLE 3 Survival estimates from start of oral etoposide by cancer type and for all tumours combined





A. Survival point estimates and 95% confidence intervals at 1-year intervals
1 year 11.1 (3.0–41.0) – 24.3 (13.8–42.9) 23.1 (8.6–62.3) 50.0 (26.9–92.9) 62.5 (42.8–91.4) 26.4 (19.4–36.0)
2 years 5.6 (0.1–37.3) – 4.5 (2.7–24.0) 7.7 (1.2–50.6) 37.5 (16.2–86.8) 41.7 (22.9–75.8) 13.7 (8.5–22.1)
3 years 5.6 (0.1–37.3) – 4.1 (0.1–23.6) – 12.5 (2.1–76.2) 27.8 (12.2–63.3) 7.4 (3.7–14.8)
4 years – – – – 12.5 (2.1–76.2) 20.8 (7.7–56.6) 4.2 (1.4–12.7)
5 years – – – – 12.5 (2.1–76.2) 4.2 (1.4–12.7)
B.Median survivala and interquartile range inmonths by cancer type
3.6 (1.9–4.8) 4.0 (2.4–7.8) 4.1 (1.4–11.7) 6.5 (4.2–11.4) 9.2 (7.2–24.6) 15.5 (4.8–35.5) 5.5 (2.4–11.3)
aIncluding patients alive at end of follow-up.
tumours’, two cycles for neuroblastoma and ependymoma and three
for Ewing sarcoma. The maximum prescribed to any patient was nine
cycles.
The relationships between age, sex, tumour type, number of prior
lines of treatment and survival were investigated with a Cox regres-
sionmodel (Table 4). Tumour typewas significantly associatedwith sur-
vival in both univariable and multivariable models. Survival of patients
with ependymomas andCNS embryonal tumourswas significantly bet-
ter than with osteosarcoma in the univariable model. In the multivari-
able model, patients with CNS embryonal tumours remained signifi-
cantly better; adjusted HR 0.34 (0.14–0.81). Number of prior lines of
treatment was also significantly associated with survival in both uni-
variable andmultivariable models. In themultivariable model, patients
with three or more previous regimens had significantly worse survival
than those forwhomoral etoposidewas the first recorded regimen;HR
2.19 (1.10–4.36).No relationshipwasobservedbetweenageor sex and
survival.
Because oral etoposide is usually given in the palliative setting and
frequently when other more intensive or hospital-based regimens are
deemed inappropriate, we examined the proportion for whom oral
etoposide was the final regimen prescribed prior to death. In total,
27 patients (23%) were prescribed a subsequent SACT regimen. In 11
cases, a different regimen was given within approximately 2 months
of the first prescription of oral etoposide (cisplatin or carboplatin and
etoposide n=3, temozolomide+/− irinotecan n= 2, liposomal doxoru-
bicin n=2, cytarabine+/− idarubicin n=2, denosumab n=1 and dasa-
tinib n = 1). Fourteen additional cases had 11 other subsequent regi-
mens at 85–563 days from the start of oral etoposide, and two patients
were treated with a second course of oral etoposide 175 and 417 days
after the first course. There was a nonsignificant trend towards better
survival in patientswho received additional chemotherapy subsequent
to oral etoposide: adjusted HR for death in those who had subsequent
chemotherapy was 0.62 (0.36–1.09) compared to those for whom oral
etoposide was the final SACT regimen. When patients who received
subsequent chemotherapywere removed from the dataset, medianOS
was 4.7 months (IQR 2.0–10.1). In this subset of patients age, tumour
type and number of lines of chemotherapy all correlated with survival
on univariable analysis, with better survival in younger patients, those
with ependymomas and CNS embryonal tumours and those for whom
oral etoposidewas the first recorded regimen (Table 4) but no variables
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F IGURE 2 Kaplan–Meier overall survival curves of (A) all patients in the final cohort (grey shading indicates 95% confidence intervals), and (B)
individual tumour classes
remained significant at a significance p-value of .05 in themultivariable
model.
4 DISCUSSION
We report here the largest series to date of children and young adults
treated with oral etoposide as a single agent, the largest to report
OS, and the first to use routinely collected population-level data.
Median survival in our series across the entire cohort of 115 chil-
dren and young people was 5.5 months, and 4.7 months in the 88
patients for whomoral etoposidewas the final chemotherapy regimen.
There are no other directly comparable survival data reported. The
series of mixed childhood brain tumours (n = 14),15 childhood recur-
rent ependymomas (n= 12)20 and locally recurrent medulloblastomas
(n = 8)24 that reported survival data are too small to make meaning-
ful comparisons with our series. Podda and colleagues reported the
survival outcomes of 58 children and young people with Ewing sar-
coma treated at a single centre, the Istituto Tumori, Milan.19 This is
the largest series of a single tumour type in the literature with survival
outcomes. The median survival of 11 months was longer than the 4-
monthmedian survival of 21 children and young people with recurrent
Ewing sarcoma in our national series. Some patients in theMilan series
had concomitant or subsequent radiotherapy and/or surgery, and/or
FRASER ET AL. 9 of 11
subsequent chemotherapy. A total of 27 patients in our national series
had additional chemotherapy but it was not possible to identify how
many received radiotherapy or surgery from the SACT database, and
the small number of cases in both series precludes any robust compar-
ison.
A key feature of our report is its ‘real world’ setting: oral etopo-
side was not given according to a standardised dose, schedule or speci-
fied number of cycles, or at a predefined point in the treatment path-
way, and compliance with prescribed treatment was not monitored.
It is a regimen that is frequently, though not exclusively, used ‘when
all else has failed’. Given the number of SACT regimens used across
the whole spectrum of CTYA cancer and the variable nomenclature
applied by individual hospitals to chemotherapy regimens within the
SACT database, an analysis of the place of oral etoposide within the
overall patient pathway would have been highly complex. However,
one can assume given the short median survival, and in the majority
no evidence of further chemotherapy, that in most cases it was used
as a palliative regimen. It is important to recognise, therefore, that in
our national series more than half of cases had only a single cycle of
treatment, andmore than half with bone sarcomas and ‘other tumours’
died within 6 months of starting treatment. This finding is in keeping
with response durations in the literature, which are typically short-
lived. The handful of cases with prolonged survival in our series and
other reported series,14,20 are intriguing and demonstrate that in a
small minority of cases, oral etoposide may have useful activity. How-
ever, we also found that survival varies between cancer types, and pro-
longed survival in some cases may reflect natural history rather than
etoposide activity. The SACT dataset was not collected throughout the
whole study period so we could not identify the patients in our series
who definitively did not receive oral etoposide. Therefore, it was not
possible to examine whether treatment with oral etoposide correlated
with survival. In our series, oral etoposide was the final chemother-
apy regimen in over 75% cases. In the minority who did receive
further chemotherapy, approximately one-third initiated a different
regimen within 2 months of starting oral etoposide, implying that
etoposide had limited or no benefit. The remaining cases started alter-
native treatment up to 14months after the start of etoposide.
Toxicities of at least grade 3 in other reported series include myelo-
suppression, infections, mucositis, diarrhoea, nausea, vomiting and
alopecia and aminority developed therapy-inducedmalignancies, prin-
cipally AML.14,19 Although severe toxicities are infrequent, they are
not trivial for the patients who experience them, and toxicities should
be considered in the context thatmost patients have only a single cycle
of treatment and diewithin a year. Quality of life has not been reported
in any study to date and only three have attempted to record symp-
tomatic response or performance status: ‘useful palliation’ of unknown
duration was reported in one of 15 children with mixed cancers11;
two children with recurrent ependymoma had no change in neuro-
logical findings or performance status9; and two children with recur-
rent medulloblastoma had improved neurological symptoms but no
improvement in performance status.24 Taking the published childhood
data and our findings together, there remains significant uncertainty
whether oral etoposide prolongs survival or improves quality of life
compared to no treatment despite over two decades of its use in
children and young people treated near the end of life. It undoubt-
edly causes toxicity. There have been no randomised studies against
placebo or no treatment. Given the combination of typically short-
lived responses reported in the literature, short median survival in this
and previous studies, and significant toxicity in a minority of patients,
more robust data are needed in this disease setting to determine
whether oral etoposide contributes usefully to patient care. Ideally, a
randomised, placebo-controlled trial should be undertaken, but as a
minimum well-designed, prospective study that collects accurate data
on symptom improvement and quality of life would bewelcome.
We acknowledge some limitations of our study, which include lack
of data on the prescribed dose and schedule of etoposide and incom-
plete data on the number of cycles prescribed. Ascertainment for the
SACT dataset is recognised to be worse for CTYA cancers than for
those in older adults, due in part to delayed introduction of routine
electronic prescribing for children compared to adults, and worse for
oral chemotherapy than for SACT delivered by other routes. Toxicity
is not recorded in the SACT dataset and could therefore not be anal-
ysedhere, andwedid not havedata on treatmentmodalities other than
SACT that took place subsequent to oral etoposide.We are aware that
the SACT database during the period was incomplete29 and that the
collection of SACT data relied on the availability of electronic prescrib-
ing, which was not universal in paediatric cancer centres throughout
the study period. Moreover, some patients included in our dataset may
have started oral etoposide prior to the start of the SACT dataset and
otherswhowere diagnosed after 1995 and treatedwith oral etoposide
before the start of SACT data collection could not be identified. The-
oretically, the noninclusion of cases treated prior to the SACT dataset
who had short survival may have led to relative overestimation of sur-
vival in those caseswho survived long enough to be included. However,
the likelihood of significant bias is small, as most patients had only one
or two cycles of treatment, irrespective of cancer type. Although our
data were unselected and included all children and young people for
whom there were data in the SACT database, missing data from some
centres may have introduced additional systematic biases.
Nevertheless, by combining routinely collected, population-level
diagnostic treatment and outcome data, we describe here the first
report of oral etoposide use in a national, unselected cohort of children
and young people.Wepresent data onOS in children and young people
prescribed oral etoposide for the treatment of cancer. We have iden-
tified differences in survival between cancers of different histologies.
Whether these differences are due to differential activity of etopo-
side or variable natural histories of the cancers concerned is unclear;
there is no evidence in our data that patients with CNS embryonal
tumours or ependymomas, despite living longer, received more cycles
of etoposide than patients with other cancers. Our analysis identifies
weaknesses in the literature on rare cancer treatments that are typical
of the clinical scenario of relapsed cancer in children and young peo-
ple: a concentration on imaging response as the primary measure of
activity, lack of data on survival, lack of randomised evidence to drive
10 of 11 FRASER ET AL.
treatment, little data on whether symptoms are effectively palliated,
but nevertheless the incorporation of therapy into routine patient care.
This study represents an exemplar of our ability to describe the effec-
tiveness of treatment for rare cancerswhere clinical trial data are lack-
ing. We have identified the need for a well-designed clinical trial to
determinewhether a longstanding andwidespreadpalliative childhood
cancer treatment is of benefit to the patients who receive it.
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